Technology Bundle ID
NCI-E-048-2012

Prognostic Biomarkers for Patients with Early Stage Lung Cancer

Applications
Lead Inventors
Curtis Harris (NCI)
Co-Inventors
Aaron Schetter (NCI)
Hirokazu Okayama (NCI)
Ichiro Akagi (NCI)
Development Status
Pre-clinical (in vivo)
ICs

Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20-30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic benefit.

Utilizing patient samples, the investigators conducted a retrospective study in eight patient cohorts that validated the gene classifier set. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy.

Commercial Applications
  • Method to determine the prognosis of patients with lung cancer.
  • Method to select more effective treatment and post-operative follow-up for patients with early stage lung cancer.
Competitive Advantages
  • Assays were validated in human tissue samples and eight different patient cohorts.

Request More Info

Licensing Contact: